A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek co najmniej 18 lat
  • Nowotwór zaawansowany lub przerzutowy, który pogorszył się po przynajmniej jednym poprzednim leczeniu systemowym
  • Potwierdzony wysoki poziom białka HER2 (IHC 3+) w badaniu centralnym
  • Co najmniej jeden mierzalny guz w badaniu obrazowym
  • Dobry stan ogólny (ECOG 0-1)
  • Przewidywana długość życia co najmniej 3 miesiące
  • Wystarczająca funkcja organów wewnętrznych
  • Ujemny test ciąży u kobiet mogących mieć dzieci

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 10, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (28)

Arizona Oncology Associates, PC - NAHOA

Prescott, United States

Rocky Mountain Cancer Center

Littleton, United States

Florida Cancer Specialists - South

Fort Myers, United States

Florida Cancer Specialists - Lake Nona

Orlando, United States

Florida Cancer Specialists - North

St. Petersburg, United States

Florida Cancer Specialists - East

West Palm Beach, United States

Affiliated Oncologists

Chicago Ridge, United States

Barbara Ann Karmanos Cancer Institute

Detroit, United States

Memorial Sloan Kettering Cancer Center

New York, United States

Alliance Cancer Specialists

Horsham, United States

Tennessee Cancer Specialists

Knoxville, United States

SCRI Oncology Partners

Nashville, United States

Texas Oncology - West Texas

Amarillo, United States

Texas Oncology - DFW

Dallas, United States

MD Anderson Cancer Center

Houston, United States

Texas Oncology - San Antonio

San Antonio, United States

Blue Ridge Cancer Care

Roanoke, United States

National Cancer Center Suwon

Suwon, South Korea

The Catholic University of Korea St Vincent's Hospital

Suwon, South Korea

Chonnam National University Hwasun Hospital

Hwasun-Eup, South Korea

Samsung Medical Center

Gangnam-gu, South Korea

Korea University Guro Hospital

Guro-gu, South Korea

Seoul National University Hospital

Jongno-gu, South Korea

Severance Hospital

Seodaemun-gu, South Korea

The Catholic University of Korea Seoul St. Mary's Hospital

Seoul, South Korea

Asan Medical Center

Seoul, South Korea

Seoul National University Bundang Hospital

Seoul, South Korea

Hospital Regional Universitario de Malaga - Hospital General

Málaga, Spain

Trial contact

Clinical Trial Disclosure & Transparency

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.